Ryan Marando

Today we announced the first patient enrollment in the landmark BENEFIT-HF trial at North Central Heart - a division of the Avera Heart Hospital in Sioux Falls, SD by Dr. Orvar Jonsson. BENEFIT-HF is expected to be one of the largest therapeutic cardiac device trials ever performed in heart failure, enrolling 2,500 patients at approximately 150 centers in the United States and Germany. The prospective, randomized, controlled, multicenter trial is supported by CMS Category B IDE coverage and designed to evaluate all-cause mortality and heart failure decompensation events in a significantly expanded heart failure population. Learn more: barost.im/4nsxMgV

Today CVRx announced the initiation of the BENEFIT-HF clinical trial, a landmark randomized study supported by CMS Category B IDE coverage and designed to evaluate the impact of Barostim in a significantly expanded heart failure population. The BENEFIT-HF trial is expected to be one of the largest therapeutic cardiac device trials ever performed in heart failure, randomizing 2,500 patients in approximately 150 centers in the United States and Germany. The primary endpoint will be a composite of all-cause mortality and heart failure decompensation events. Enrollment is expected to begin in the first half of 2026. Learn more: barost.im/4jUEH0f

Join the @CardioBusiness webinar on May 22 to learn from expert faculty about Duke University Health System's experience integrating #Barostim into their comprehensive #heartfailure program. 📅 Thursday, May 22, 1:00 PM ET 👨‍⚕️ Faculty: @FudimMarat, MD, MHS; Joanna Kipnes, MD, MS, FHM; Bonnie Handke, RN, MBA 🔗Register here: barost.im/May2025_CVBusiness…

Presented today at #THT2025 and published in the @JCardFail, new real-world evidence demonstrated large and statistically significant reductions in hospital visits and length of stay in #Barostim patients with #heartfailure and reduced ejection fraction. The analysis was performed using the Premier Healthcare Database (PHD), an all-payer database, with 306 Barostim patients identified. The evidence found: • 86% reduction in all-cause hospital visits (p<0.0001) • 84% reduction in cardiovascular hospital visits (p<0.0001) • 85% reduction in heart-failure hospital visits (p<0.0001) Read the press release to learn more: barost.im/42P7Un3 See the full analysis in the Journal of Cardiac Failure: barost.im/jcf Dive deeper into the data, listen to the Brain-Heart Continuum podcast: lnkd.in/gKH947N5

Today we announced our third quarter results and provided a business outlook for the rest of 2024. We are pleased to share these milestones: -Active US implanting centers increased 31% over prior year Q3 -US HF revenue increased 30% over prior year Q3 -Increased worldwide revenue 27% over prior year Q3 -CMS reassigned Barostim to a higher paying MS-DRG for inpatient procedures -AMA CPT® Editorial Panel accepted new CPT Category I codes for Barostim -New quality of life data was published in JACC: Heart Failure Learn more: barost.im/3AgAnGu

Reimbursement News: Today the American Medical Association CPT Editorial Panel accepted new CPT Category I codes for #Barostim. “The Category I code designation represents an important milestone for the company and is a testament to the increased adoption, safety, and effectiveness of Barostim as an important option for patients suffering from the debilitating symptoms of heart failure. We greatly appreciate the support and guidance that the Society of Vascular Surgery and American College of Cardiology provided throughout this process,” said Kevin Hykes, President and CEO of CVRx. The codes are expected to be implemented on January 1, 2026. Read the full press release: barost.im/3Agzdum

That's a wrap on day 1 of the #ASCENDHF Fellows Summit! It was jam packed with didactic presentations, discussions, and interactive sessions. Thanks to the ASCEND Course Directors (@shelleyhallmd, @JeffTeuteberg, MD, @AHajduczok, MD), Faculty (@RichaGuptaMD, Brian Howard, MD, @nyravalmd, @PeterEckmanMD, @echungMD) and Fellows for a productive and engaging day.

We're proud to partner with Drs. Abhijit Desai and Neal Dollin and the team @mercy_health West Hospital on their first #Barostim implant - offering a novel device therapy option for their symptomatic #heartfailure patients. #cardiology #CardioTwitter #vascularsurgery

We are pleased to share a new publication in JACC Journals JACC: Heart Failure by Dr. Sam Sears and his colleagues demonstrating the details of long-term quality of life improvements with #Barostim in patients with NYHA Class II or III symptoms and an LVEF ≤35% The authors report that patients had persistent improvement in both the emotional and physical components of the Minnesota Living with Heart Failure Questionnaire after 2 years follow-up. Patients’ ability to work around the house, sleep, do things with friends and family were improved along with improved shortness of breath and fatigue. Emotionally, patients were less depressed, had improved locus of control and did not feel as if they were a burden on friends and family. Even the EuroQual-5D instrument demonstrated long-term benefit with increase mobility and ability to perform usual activities along with decreased pain and discomfort. Read the article here: authors.elsevier.com/a/1jgWX… ISI: barost.im/ISI

Thank you to @SujModi, @RMotaganahalli and rest of the team @IU_Health and @IUCVInstitute for partnering with us to offer #Barostim as an option within their comprehensive #heartfailure program for patients looking to regain their quality of life!